{"id":22435,"date":"2023-03-21T10:29:13","date_gmt":"2023-03-21T17:29:13","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=22435"},"modified":"2025-07-17T09:29:17","modified_gmt":"2025-07-17T16:29:17","slug":"velcade-bortezomib-a-promising-treatment-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/","title":{"rendered":"Velcade (Bortezomib): Un tratamiento prometedor para el mieloma m\u00faltiple"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">El mieloma m\u00faltiple es un tipo de c\u00e1ncer prevalente en muchas partes del mundo. Esta afecci\u00f3n afecta las c\u00e9lulas plasm\u00e1ticas de la m\u00e9dula \u00f3sea y es com\u00fan entre los hombres mayores de 60 a\u00f1os. Puede ser mortal si no se trata.&nbsp;<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-77464d26dd6536fbc784bfab0efda8e0\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista \t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p><span style=\"font-weight: 400;\">La m\u00e9dula \u00f3sea es la parte del cuerpo responsable de producir diferentes c\u00e9lulas sangu\u00edneas. Cuando se ve afectada por el c\u00e1ncer, las c\u00e9lulas anormales que se producen se propagan a otras partes del cuerpo; de ah\u00ed el t\u00e9rmino mieloma m\u00faltiple.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Aunque el mieloma m\u00faltiple es una enfermedad potencialmente mortal, estudios han revelado la eficacia de un medicamento para controlar sus s\u00edntomas y ayudar a los pacientes a vivir con mayor comodidad. En este art\u00edculo, analizaremos este medicamento, Velcade (bortezomib), su tratamiento, administraci\u00f3n, dosis, efectos secundarios y posible costo.<\/span><\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#What_Is_Velcade\" >\u00bfQu\u00e9 es Velcade?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#What_Is_Velcade_Used_For\" >\u00bfPara qu\u00e9 se utiliza Velcade?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#How_Does_It_Work\" >\u00bfC\u00f3mo funciona?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#Drug_Administration\" >Administraci\u00f3n de Medicamentos<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#Velcade_Side_Effects\" >Efectos secundarios de Velcade<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#Cost\" >Costo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-what-is-velcade\"><span class=\"ez-toc-section\" id=\"What_Is_Velcade\"><\/span>\u00bfQu\u00e9 es Velcade?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Velcade es un medicamento anticancer\u00edgeno que se utiliza para tratar enfermedades como el mieloma m\u00faltiple y el linfoma de c\u00e9lulas del manto. Generalmente se administra a personas cuyas afecciones no han mejorado tras diferentes tratamientos. El medicamento act\u00faa destruyendo las c\u00e9lulas cancerosas.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Se fabric\u00f3 por primera vez en 1995 en Myogenics y se conoc\u00eda como PS-341. Para demostrar su eficacia, se prob\u00f3 en un peque\u00f1o ensayo cl\u00ednico de fase 1 en pacientes con mieloma m\u00faltiple ese mismo a\u00f1o. Tras obtener resultados positivos, Millenium Pharmaceuticals lo lanz\u00f3 para ensayos cl\u00ednicos adicionales en 1999.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Sin embargo, no fue hasta 2003, 8 a\u00f1os despu\u00e9s de su s\u00edntesis, que obtuvo el reconocimiento. <\/span><a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/velcade-bortezomib-information#:~:text=The%20Food%20and%20Drug%20Administration,on%20the%20most%20recent%20therapy.\"><span style=\"font-weight: 400;\">Aprobaci\u00f3n de la Administraci\u00f3n de Alimentos y Medicamentos<\/span><\/a><span style=\"font-weight: 400;\"> En Estados Unidos, se utiliza como opci\u00f3n de tratamiento para el mieloma m\u00faltiple refractario. En 2005, la FDA tambi\u00e9n aprob\u00f3 el bortezomib como opci\u00f3n de tratamiento para personas con mieloma m\u00faltiple que hab\u00edan recibido al menos una terapia previa, y en 2008, se aprob\u00f3 como tratamiento inicial para pacientes con mieloma m\u00faltiple.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Finalmente, se aprob\u00f3 para el retratamiento de pacientes con mieloma m\u00faltiple en agosto de 2014 y para el tratamiento del linfoma de c\u00e9lulas del manto en octubre de 2014. Bortezomib se puede tomar solo o con otros medicamentos contra el c\u00e1ncer como melfal\u00e1n, doxorrubicina liposomal, panobinostat y <a href=\"https:\/\/www.thalidomidetrust.org\/about-us\/about-thalidomide\/\">talidomida<\/a>. Tambi\u00e9n se puede tomar con esteroides como la prednisolona.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-velcade-used-for\"><span class=\"ez-toc-section\" id=\"What_Is_Velcade_Used_For\"><\/span>\u00bfPara qu\u00e9 se utiliza Velcade?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El Bortezomib se utiliza para tratar el mieloma m\u00faltiple y el linfoma de c\u00e9lulas del manto. Ambas afecciones son tipos de c\u00e1ncer, y el medicamento act\u00faa eliminando las c\u00e9lulas cancerosas y logrando la remisi\u00f3n. Sin embargo, tenga en cuenta que el medicamento no cura ninguna de estas afecciones, ya que solo las trata y ayuda a lograr la remisi\u00f3n.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-does-it-work\"><span class=\"ez-toc-section\" id=\"How_Does_It_Work\"><\/span>\u00bfC\u00f3mo funciona?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"236\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2.jpg\" alt=\"Patient receiving Velcade treatment for multiple myeloma.\" class=\"wp-image-26120\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2-300x169.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2-86x48.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2-167x94.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2-280x157.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/velcade-patient2-370x208.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p><span style=\"font-weight: 400;\">El Bortezomib pertenece a una clase de f\u00e1rmacos contra el c\u00e1ncer conocidos como inhibidores del proteasoma. Restringe y previene el crecimiento de los proteasomas en las c\u00e9lulas humanas.&nbsp;&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Los proteasomas existen en las c\u00e9lulas y su funci\u00f3n principal es descomponer las prote\u00ednas que la c\u00e9lula no necesita. Por lo tanto, el uso de inhibidores de proteasomas impide que estos realicen su funci\u00f3n, lo que provoca la acumulaci\u00f3n de prote\u00ednas en las c\u00e9lulas, provocando su muerte.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">En pacientes con mieloma m\u00faltiple y linfoma de c\u00e9lulas del manto, el bortezomib act\u00faa sobre las c\u00e9lulas cancerosas, ya que estas son m\u00e1s sensibles a sus efectos. Impide que los proteasomas de estas c\u00e9lulas realicen sus funciones, lo que provoca su muerte.&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-administration\"><span class=\"ez-toc-section\" id=\"Drug_Administration\"><\/span>Administraci\u00f3n de Medicamentos<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El Bortezomib se administra generalmente bajo la piel (v\u00eda subcut\u00e1nea) o en el torrente sangu\u00edneo (v\u00eda intravenosa). Por v\u00eda subcut\u00e1nea, puede recibir la inyecci\u00f3n en el muslo o el abdomen. Independientemente de d\u00f3nde se administre la inyecci\u00f3n, debe cambiar el lugar de inyecci\u00f3n cada vez para reducir el dolor y las lesiones en la piel.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">El medicamento se administra dos veces por semana durante dos semanas. Despu\u00e9s de dos semanas, hay un per\u00edodo de descanso de 13 d\u00edas, completando as\u00ed las tres semanas del ciclo. Recibir\u00e1 este ciclo de tratamiento. <\/span><span style=\"font-weight: 400;\">por un m\u00e1ximo de 8 ciclos.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Si los niveles de suero M (un tipo de prote\u00edna producida por las c\u00e9lulas de mieloma) en su cuerpo se han reducido, el tratamiento est\u00e1 funcionando y deber\u00e1 completar dos ciclos m\u00e1s. Continuar\u00e1 ocho ciclos m\u00e1s si los niveles no se han reducido significativamente. Sin embargo, los ciclos pueden variar seg\u00fan la gravedad de la afecci\u00f3n. Por lo tanto, su m\u00e9dico determinar\u00e1 cu\u00e1l es el m\u00e1s adecuado para usted.<\/span><\/p>\n\n\n\n<div  id=\"call-to-action-0f3ced3a3f7d862d1b674fa3dcb084ce\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAsistencia financiera\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-velcade-side-effects\"><span class=\"ez-toc-section\" id=\"Velcade_Side_Effects\"><\/span>Efectos secundarios de Velcade<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">Algunos efectos secundarios asociados con el uso de bortezomib incluyen:<\/span><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><span style=\"font-weight: 400;\">Debilidad&nbsp;<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Constipaci\u00f3n<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">N\u00e1useas<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Mareo<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">V\u00f3mitos<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">P\u00e9rdida de apetito<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Dolor<\/span><\/li>\n\n\n\n<li><span style=\"font-weight: 400;\">Dolor de cabeza<\/span><\/li>\n<\/ul>\n\n\n\n<p><span style=\"font-weight: 400;\">En casos extremos, las n\u00e1useas, la diarrea y los v\u00f3mitos pueden agravarse. Consulte a su farmac\u00e9utico o m\u00e9dico si experimenta efectos secundarios graves.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Otro efecto secundario peculiar que puede experimentar despu\u00e9s de usar el medicamento es <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3437249\/#:~:text=The%20tumor%20lysis%20syndrome%20occurs,hyperkalemia%2C%20hyperphosphatemia%2C%20and%20hypocalcemia.\">s\u00edndrome de lisis tumoral<\/a>Este efecto secundario se produce debido a la r\u00e1pida destrucci\u00f3n de las c\u00e9lulas cancerosas. Para reducir el riesgo de este efecto secundario, se recomienda beber abundante agua y tomar los medicamentos adicionales recomendados seg\u00fan las indicaciones.&nbsp;<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">La anemia es otro efecto secundario que podr\u00eda experimentar con el bortezomib. Esto se debe a que el medicamento podr\u00eda disminuir la cantidad de gl\u00f3bulos rojos en el cuerpo. Este efecto secundario provoca cansancio y debilidad.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">Finalmente, la erupci\u00f3n cut\u00e1nea es otro efecto secundario que se presenta con el uso de este medicamento. Sin embargo, la erupci\u00f3n no deber\u00eda ser grave y deber\u00eda desaparecer r\u00e1pidamente. El desarrollo de reacciones al\u00e9rgicas graves al bortezomib es poco com\u00fan y no se ha reportado en el... <\/span><a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00153920\"><span style=\"font-weight: 400;\">estudios cl\u00ednicos<\/span><\/a><span style=\"font-weight: 400;\"> Se realiza para comprobar la eficacia del medicamento. Por lo tanto, si experimenta una reacci\u00f3n al\u00e9rgica grave, debe contactar inmediatamente a su m\u00e9dico o farmac\u00e9utico.<\/span><\/p>\n\n\n\n<p><span style=\"font-weight: 400;\">&nbsp;<\/span><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cost\"><span class=\"ez-toc-section\" id=\"Cost\"><\/span>Costo<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><span style=\"font-weight: 400;\">El precio promedio de venta al p\u00fablico de bortezomib es de aproximadamente $1,644 por un polvo para inyecci\u00f3n intravenosa. Sin embargo, existen muchos factores que pueden afectar el precio exacto que paga, como su ubicaci\u00f3n, seguro m\u00e9dico y plan de salud.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>El mieloma m\u00faltiple es un tipo de c\u00e1ncer prevalente en muchas partes del mundo. Esta afecci\u00f3n afecta las c\u00e9lulas plasm\u00e1ticas de la m\u00e9dula \u00f3sea y es com\u00fan entre los hombres mayores de 60 a\u00f1os.<\/p>","protected":false},"author":23,"featured_media":22436,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[13],"tags":[29],"class_list":["post-22435","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","tag-miralle-kaldass"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma<\/title>\n<meta name=\"description\" content=\"Learn about Velcade (Bortezomib), a treatment for multiple myeloma. Topics include how the drug works, administration, and side effects.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Learn about Velcade (Bortezomib), a treatment for multiple myeloma. Topics include how the drug works, administration, and side effects.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-21T17:29:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-17T16:29:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Miralle Kaldass\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Miralle Kaldass\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/\"},\"author\":{\"name\":\"Miralle Kaldass\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/b67a794f5dbb4ca54f30cb87e08c065d\"},\"headline\":\"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma\",\"datePublished\":\"2023-03-21T17:29:13+00:00\",\"dateModified\":\"2025-07-17T16:29:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/\"},\"wordCount\":933,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/myeloma.jpg\",\"keywords\":[\"Miralle Kaldass\"],\"articleSection\":[\"Cancer\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/\",\"name\":\"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/myeloma.jpg\",\"datePublished\":\"2023-03-21T17:29:13+00:00\",\"dateModified\":\"2025-07-17T16:29:17+00:00\",\"description\":\"Learn about Velcade (Bortezomib), a treatment for multiple myeloma. Topics include how the drug works, administration, and side effects.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/myeloma.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/myeloma.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Multiple Myeloma, a type of cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/cancer\\\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/b67a794f5dbb4ca54f30cb87e08c065d\",\"name\":\"Miralle Kaldass\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8da1d0d99ef07d2baccce4b8a6cc7c4ec96f35ff229610275075fb1b713e5bcb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8da1d0d99ef07d2baccce4b8a6cc7c4ec96f35ff229610275075fb1b713e5bcb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8da1d0d99ef07d2baccce4b8a6cc7c4ec96f35ff229610275075fb1b713e5bcb?s=96&d=mm&r=g\",\"caption\":\"Miralle Kaldass\"},\"description\":\"Miralle Kaldass was born and raised in Egypt. She received her pharmacy degree from the Faculty of Pharmacy, Cairo University, and has 5 years of experience as a pharmacist. The most rewarding part of her job is providing patient care where a patient's health can improve and allow them to live a better life. Her areas of expertise include long-term care with nursing homes and hospices, specialty pharmacy, and TPN. In her free time, she enjoys going to the gym, shopping, and walking by the beach.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/miralle\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Velcade (Bortezomib): Un tratamiento prometedor para el mieloma m\u00faltiple","description":"Aprenda sobre Velcade (Bortezomib), un tratamiento para el mieloma m\u00faltiple. Los temas incluyen c\u00f3mo funciona el medicamento, su administraci\u00f3n y sus efectos secundarios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/","og_locale":"es_MX","og_type":"article","og_title":"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma","og_description":"Learn about Velcade (Bortezomib), a treatment for multiple myeloma. Topics include how the drug works, administration, and side effects.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2023-03-21T17:29:13+00:00","article_modified_time":"2025-07-17T16:29:17+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg","type":"image\/jpeg"}],"author":"Miralle Kaldass","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Miralle Kaldass","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/"},"author":{"name":"Miralle Kaldass","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/b67a794f5dbb4ca54f30cb87e08c065d"},"headline":"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma","datePublished":"2023-03-21T17:29:13+00:00","dateModified":"2025-07-17T16:29:17+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/"},"wordCount":933,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg","keywords":["Miralle Kaldass"],"articleSection":["Cancer"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/","url":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/","name":"Velcade (Bortezomib): Un tratamiento prometedor para el mieloma m\u00faltiple","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg","datePublished":"2023-03-21T17:29:13+00:00","dateModified":"2025-07-17T16:29:17+00:00","description":"Aprenda sobre Velcade (Bortezomib), un tratamiento para el mieloma m\u00faltiple. Los temas incluyen c\u00f3mo funciona el medicamento, su administraci\u00f3n y sus efectos secundarios.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg","width":1280,"height":853,"caption":"Multiple Myeloma, a type of cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/cancer\/velcade-bortezomib-a-promising-treatment-for-multiple-myeloma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/es\/"},{"@type":"ListItem","position":2,"name":"Velcade (Bortezomib): A Promising Treatment for Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/b67a794f5dbb4ca54f30cb87e08c065d","name":"Miralle Kaldass","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8da1d0d99ef07d2baccce4b8a6cc7c4ec96f35ff229610275075fb1b713e5bcb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8da1d0d99ef07d2baccce4b8a6cc7c4ec96f35ff229610275075fb1b713e5bcb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8da1d0d99ef07d2baccce4b8a6cc7c4ec96f35ff229610275075fb1b713e5bcb?s=96&d=mm&r=g","caption":"Miralle Kaldass"},"description":"Miralle Kaldass naci\u00f3 y creci\u00f3 en Egipto. Se licenci\u00f3 en Farmacia en la Facultad de Farmacia de la Universidad de El Cairo y cuenta con cinco a\u00f1os de experiencia como farmac\u00e9utica. Lo m\u00e1s gratificante de su trabajo es brindar atenci\u00f3n m\u00e9dica a pacientes, donde la salud de estos puede mejorar y les permite vivir una vida mejor. Sus \u00e1reas de especializaci\u00f3n incluyen cuidados a largo plazo en residencias de ancianos y hospicios, farmacia especializada y TPN. En su tiempo libre, disfruta de ir al gimnasio, ir de compras y pasear por la playa.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/miralle\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Miralle Kaldass","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/miralle\/"},"uagb_comment_info":0,"uagb_excerpt":"Multiple myeloma is a type of cancer prevalent in many parts of the world. This condition affects the plasma cells in bone marrow and is common among male adults over 60.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",600,400,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/03\/myeloma.jpg",1280,853,false]},"rttpg_author":{"display_name":"Miralle Kaldass","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/miralle\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/cancer\/\" rel=\"category tag\">Cancer<\/a>","rttpg_excerpt":"Multiple myeloma is a type of cancer prevalent in many parts of the world. This condition affects the plasma cells in bone marrow and is common among male adults over 60.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=22435"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22435\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/22436"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=22435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=22435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=22435"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}